Effect of ovarian tumor characteristics on venous thromboembolic risk

Journal of Gynecologic Oncology

Volumn 24, Issue 1, 2012, Pages 52-58

  Bakhru, Arvind ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Histology; Ovarian neoplasms; Venous thromboembolism

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; PRIMARY PERITONEAL CANCER; PRIMARY TUMOR; UTERINE TUBE CANCER; UTERINE TUBE DISEASE; VENOUS THROMBOEMBOLISM;

EID: 84873025472     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.1.52     Document Type: Article

References (25)

1. Black D, Iasonos A, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer. Gynecol Oncol 2007;107:66-70.
2. Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007;105:784-90.
3. Tateo S, Mereu L, Salamano S, Klersy C, Barone M, Spyropoulos AC, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 2005;99:119-25.
4. Kahn SR, Ducruet T, Lamping DL, Arsenault L, Miron MJ, Roussin A, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 2005;165:1173-8.
5. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86.
6. Bradley CT, Brasel KJ, Miller JJ, Pappas SG. Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery. Ann Surg Oncol 2010;17:31-9.
7. Trousseau A. Clinique médicale de l'Hôtel-Dieu de Paris. Paris: J. B. Bailliere et Fils; 1865.
8. Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989;42:805-9.
9. Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999;84:437-45.
10. Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, Kikuchi K, et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer 2009;101:2023-9.
11. Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007;96:290-5.
12. von Tempelhoff GF, Heilmann L, Hommel G, Schneider D, Niemann F, Zoller H. Hyperviscosity syndrome in patients with ovarian carcinoma. Cancer 1998;82:1104-11.
13. Satoh T, Oki A, Uno K, Sakurai M, Ochi H, Okada S, et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 2007;97:1053-7.
14. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-64.
15. Fotopoulou C, duBois A, Karavas AN, Trappe R, Aminossadati B, Schmalfeldt B, et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 2008;26:2683-9.
16. Bergqvist D. Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis. J Surg Oncol 2007;95:167-74.
17. Peedicayil A, Weaver A, Li X, Carey E, Cliby W, Mariani A. Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol 2011;121:64-9.
18. Lim MC, Lee HS, Kang S, Seo SS, Lee BY, Park SY. Minimizing tumor burden by extensive cytoreductive surgery decreases postoperative venous thromboembolism in ovarian clear cell carcinoma. Arch Gynecol Obstet 2010;281:329-34.
19. Duska LR, Garrett L, Henretta M, Ferriss JS, Lee L, Horowitz N. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol 2010;116:374-7.
20. Matsuura Y, Robertson G, Marsden DE, Kim SN, Gebski V, Hacker NF. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2007;104:406-10.
21. Martino MA, Williamson E, Rajaram L, Lancaster JM, Hoffman MS, Maxwell GL, et al. Defining practice patterns in gynecologic oncology to prevent pulmonary embolism and deep venous thrombosis. Gynecol Oncol 2007;106:439-45.
22. Einstein MH, Kushner DM, Connor JP, Bohl AA, Best TJ, Evans MD, et al. A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients. Obstet Gynecol 2008;112:1091-7.
23. White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165:1782-7.
24. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-505.
25. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:381S-453S.